source
- Diagnostic-driven therapies face patient loss due to workflow gaps, new commercialization model proposedThe sponsored article from Diaceutics highlights that while diagnostic-driven therapies are being developed faster than ever, many patients who could benefit never receive them. The authors attribu…
- Stem cell advocates anticipate FDA roundtables as peptide therapies gain regulatory footholdAt PepMed 2026, a conference focused on peptide medicines, stem cell entrepreneur Chuck Meeker said he expects the FDA to hold a series of roundtables on regenerative therapies before year‑end. He…